The Albanese Government's commitment to making healthcare more accessible and affordable is evident in its recent expansion of the Pharmaceutical Benefits Scheme (PBS). This initiative, set to take effect from June 1, 2026, will significantly reduce the cost of essential medications for Australians battling leukaemia and severe migraines.
One of the key treatments, Acalabrutinib (Calquence®), is a targeted therapy that blocks the protein necessary for cancer cell growth and survival. When combined with venetoclax, it becomes even more effective in slowing or halting the progression of chronic lymphocytic leukaemia and small lymphocytic lymphoma. These blood cancers, which affect white blood cells, can lead to a range of symptoms, including fatigue, frequent infections, swollen lymph nodes, and low blood counts. The slow development of these cancers often necessitates long-term treatment to manage the disease effectively.
The PBS expansion will benefit over 1,200 patients annually, who, without subsidy, would face exorbitant costs of $7,000 per script. This is a substantial financial burden that the government is alleviating, ensuring that these patients can access life-saving treatment without breaking the bank.
Another treatment, Blinatumomab (Blincyto®), is an immunotherapy that brings immune cells directly into contact with cancer cells, enabling the patient's immune system to target the disease more effectively. This therapy is particularly beneficial for those with precursor B-cell acute lymphoblastic leukaemia, a fast-growing and aggressive form of blood cancer that affects both the blood and bone marrow. Symptoms include fatigue, frequent infections, easy bruising or bleeding, and bone pain.
The PBS expansion will cover around 110 patients annually, who, without subsidy, would face a staggering $229,000 per course of treatment. This reduction in cost is a significant step towards making immunotherapy more accessible to those in need.
Furthermore, the PBS listing of Galacenezumab (Emgality®) will benefit patients with high-frequency episodic migraines, a condition affecting approximately 135,000 Australians annually. Emgality® works by blocking a gene-related peptide involved in migraines, reducing both the frequency and severity of attacks. Without the PBS listing, patients would pay over $500 per script, but with the subsidy, the cost is reduced to a maximum of $25 per script, or just $7.70 for those with a concession card.
Since July 2022, the Albanese Government has approved additional funding for 444 new and amended listings on the PBS, demonstrating a sustained commitment to improving healthcare affordability. Minister Butler emphasized the importance of the PBS in making Australia's health system one of the most fair and equitable in the world, ensuring that life-changing treatments are accessible to all Australians.
In my opinion, this initiative is a testament to the government's dedication to public health and its recognition of the financial burden that high-cost medications can impose on patients. By making these essential drugs more affordable, the government is not only improving health outcomes but also fostering a more equitable and compassionate healthcare system.
This expansion of the PBS is a significant step towards ensuring that all Australians, regardless of their financial situation, can access the treatments they need to lead healthy and fulfilling lives. It is a powerful example of how government policy can positively impact the lives of citizens, making a tangible difference in their daily struggles with serious health conditions.
